IP Library Granted Patent US 10,941,181
Granted Patent B2
US 10,941,181 · App. 15/226,161 · Granted Mar 9, 2021

Immunotherapy against several tumors including neuronal and brain tumors

Inventors: Toni Weinschenk (Aichwald, DE); Oliver Schoor (Tuebingen, DE); Claudia Trautwein (Wuelfrath, DE); Norbert Hilf (Kirchentellinsfurt, DE); Steffen Walter (Houston, TX); Harpreet Singh (Houston, TX)
Assignee: IMMATICS BIOTECHNOLOGIES GMBH
C07K7/06A61K35/17A61K39/0011A61M5/002C07K7/08C07K14/70539C12N5/0638G01N33/57492A61K38/00A61K2039/5154A61K2039/5158A61K2039/53A61K2039/55511A61K2039/55516A61K2039/55522A61K2039/55561A61K2039/55588A61K2039/572A61K2039/605A61K2039/6081A61K2039/6093C07K2319/00C07K2319/40C12N2501/50Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,941,181
App. No.
15/226,161
Granted
Mar 9, 2021
Kind
B2
Abstract

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Claims (9)

1. A peptide consisting of the amino acid sequence of TLVGIIVGV (SEQ ID NO: 22) in the form of pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.

2. A pegylated peptide consisting of the amino acid sequence of TLVGIIVGV (SEQ ID NO: 22) or a pharmaceutically acceptable salt thereof.

3. A composition comprising a peptide consisting of the amino acid sequence of TLVGIIVGV (SEQ ID NO: 22) in the form of pharmaceutically acceptable salt and an immune-stimulating adjuvant.

4. A composition comprising the pegylated peptide of claim 2 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5. The peptide of claim 1 , wherein the pharmaceutical pharmaceutically acceptable salt is a chloride salt or acetate salt.

6. A peptide consisting of the amino acid sequence of TLVGIIVGV (SEQ ID NO: 22), wherein at least one amino acid of the peptide is a D-amino acid.

7. The composition of claim 3 , wherein the adjuvant is selected from the group consisting of interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

8. The composition of claim 7 , wherein the adjuvant is IL-2.

9. The composition of claim 7 , wherein the adjuvant is IL-7.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2016
From: WEINSCHENK, TONI; SCHOOR, OLIVER; TRAUTWEIN, CLAUDIA; HILF, NORBERT; WALTER, STEFFEN; SINGH, HARPREET
To: IMMATICS BIOTECHNOLOGIES GMBH
Reel/Frame 039548/0333 →
Priority Claims (3)
EP 08017305 · Oct 1, 2008 · regional
EP 08017921 · Oct 13, 2008 · regional
WO PCT/EP2009/006980 · Sep 28, 2009 · international
Continuity (5)
Continuation 14562156 · Dec 5, 2014
Division 13346598 · Jan 9, 2012
Division 12571776 · Oct 1, 2009
Provisional Application 61105928 · Oct 16, 2008
Related Publication 20160376316A1 · Dec 29, 2016
Cited By (1)
US 12,234,298